Videos

The clinical research director at the UCSF Multiple Sclerosis Center discussed the efficacy of inebilizumab (Uplizna; Viela Bio) and biomarker data observed in the N-Momentum trial in NMOSD.

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed whether her and colleagues recent study results on ubrogepant aligned with previous study findings.

The clinical research director at the UCSF Multiple Sclerosis Center shared his perspective on the recent FDA approval of inebilizumab (Uplizna; Viela Bio) for NMOSD.

The internal medicine resident physician at Montefiore Health System offers insight into the combined use of CGRP medications and Botox to optimize migraine prevention in patients who have inadequate response with Botox alone.

Neurology News Network for the week ending June 20, 2020.

The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.

The clinical research director at the UCSF Multiple Sclerosis Center discussed the anticipated impact of the recent FDA approval of inebilizumab (Uplizna; Viela Bio) for NMOSD.

The neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis and co-principal investigator of the CAVS-MS study discusses the reasons for the high rates of misdiagnosed MS.

The director of the Neurology Residency Program at Weill Cornell Medicine details his first-hand experience working in the epicenter of the COVID-19 pandemic and how his department adapted.

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed how this year has proved that telemedicine is likely here to stay.

The clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research at Cleveland Clinic details the interventions for men with MS and how the study can change the discussion on masculinity norms.

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital spoke to the specific datasets she is anticipating at the AHS 2020 meeting.

Neurology News Network for the week ending June 13, 2020.

The clinical health psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic details the use of behavioral health and potential use of Conformity to Masculine Norms Inventory (CMNI) tool in multiple sclerosis care.

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to the rapid expansion of headache medicine and what new research will be discussed at AHS 2020.

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed what topics the plenary talks will cover at AHS 2020.

The group medical director of neuroscience at Genentech spoke to the findings recently presented at the 6th Annual Meeting of the European Academy of Neurology.

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to what to expect from this year’s annual scientific meeting.

The clinical healthy psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the reasoning behind his study evaluating conformity of masculine norms in patients with multiple sclerosis.

Neurology News Network for the week ending June 6, 2020.

Head of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.